2Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol,2009,118 : 5 36. 被引量：1
3Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimerr s disease., academic, industry and regulatory perspectives. Nat Rev Drug Discov, 2010, 9:560 574. 被引量：1
4Blennow K, Hampel H, Weiner M, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol, 2010, 6 131- 144. 被引量：1
5Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. Neuro Rx, 2004, 1: 213- 225. 被引量：1
6Diniz BS, Pinto Jfunior JA, Forlenza OV. Do CSF total tau, phosphorylated tau, and beta amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer s disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry, 2008,9 = 172-182. 被引量：1
7Hertze J, Minthon L, Zetterberg H, et al. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J AlzheimersDis, 2010,21:1119 1128. 被引量：1
8Gloeckner SF, Meyne F, Wagner F, et al. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis, 2008,14..17-25. 被引量：1
9Formichi P, Battisti C, Radi E, et al. Cerebrospinal fluid tau, A13, and phosphorylated tau protein for the diagnosis of Alzheimers disease. J Cell Physiol,2006, 208 .. 39-46. 被引量：1
10Hanger DP, Anderton BH, Noble W. Tau phosphorylation = the therapeutic challenge {or neurodegenerative disease. Trends Mol Med, 2009, 15: 112-119. 被引量：1
